CClinicalTrials.gg
RecruitingNCT05415878Updated Aug 19, 2026

Impact of Removable Cast Walker Design on Usability for Patients With Diabetic Foot Ulcers

An interventional study of RCW design form in Diabetes Mellitus and Foot Ulcer, sponsored by Rosalind Franklin University of Medicine and Science. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Rosalind Franklin University of Medicine and Science · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Within their lifetime, over 30% of people living with diabetes will develop a diabetic foot ulcer (DFU), many of which will never heal and may require amputation. Removable cast walkers (RCWs) are commonly prescribed to offload (treat) DFUs. While RCWs are prescribed to be worn during all weight bearing activities, adherence to this prescription is low. This is a serious concern given that low adherence predicts poor DFU healing. This study will provide pilot/feasibility data to inform a larger clinical trial to evaluate the impact of existing RCW designs on adherence and DFU healing. We will also quantify the effect of RCW form on biomechanical and self-reported measures related to usability. Our working hypothesis is that healing outcomes with a given RCW will be predicted by biomechanical and self-reported measures of RCW usability, with the predictive relationship partly explained by the effect of these measures on adherence.

02

Conditions studied

  • Diabetes Mellitus
  • Foot Ulcer
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • presence of a full thickness plantar (forefoot) diabetic foot ulcer ≥1cm2 that is being treated on an outpatient basis with a University of Texas wound classification of 1A-C or 2 A-C;
  • self-reported ability to walk for at least two continuous minutes at a self-selected speed
  • confirmation of the presence of diabetic peripheral neuropathy as identified by failure to detect a 10 gram Semmes Weinstein Monofilament on either foot at one of four sites tested (1st, 3rd, 5th metatarsal heads, and plantar surface of hallux) OR a vibration perception threshold value of 25 or more at either hallux.

Exclusion criteria

Exclusion Criteria:

  • lower extremity amputation more proximal than transmetatarsal on either limb
  • chronic kidney disease stage 4 or higher (i.e., currently undergoing dialysis or eGFR\<30 within last 60 days)
  • active Charcot neuroarthropathy
  • severe peripheral arterial disease (non-palpable pulse at posterior tibia and dorsalis pedis arteries, and an ankle brachial index\<0.7)
  • gait/balance disturbance not attributable to diabetes (e.g. neuromuscular disease or cerebrovascular vascular accident)
  • current or previous (within past year) use of an ankle-high RCW or of a contralateral lift to offset an RCW-induced LLD
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Other
    Tall RCW

    Device: RCW design form

  • Other
    Short RCW with contralateral lift

    Device: RCW design form

Interventions

  • DeviceRCW design form

    Tall RCW= a knee high removable cast walker with an offloading insole Short RCW= an ankle high (extending up the leg just past the ankle) removable cast walker with an offloading insole, paired with an external shoe lift to be used with a diabetic shoe on the contralateral limb

05

What researchers measure

Primary outcomes

  1. Offloading adherence

    Percent of weight bearing activity completed while wearing the RCW

    Time frame: days 0-28

Secondary outcomes

  1. Diabetic Foot Ulcer Healing

    Planimetric wound area

    Time frame: each clinical visit during days 0-28

  2. Cumulative plantar tissue stress

    A measure to account for the interaction between offloading capacity of the RCW and device use

    Time frame: days 0-28

Other outcomes

  1. Stability

    three separate measures taken during walking and standing (local divergence exponent of he trunk; motor equivalent index during small standing perturbations; and posterior stepping threshold for large perturbations while standing)

    Time frame: follow up visit (32-38 days after baseline)

  2. Correlates of joint pain

    Four separate biomechanical measures related to back, hip and knee pain taken during walking in a motion capture lab (peak pelvic obliquity; peak pelvic tilt; ground reaction force transience; and rate of grand reaction force loading)

    Time frame: follow up visit (32-38 days after baseline)

06

Study locations

1 of 1 sites recruiting
  • Rosalind Franklin University of Medicine and Science
    North Chicago, Illinois 60064, United States
    • Noah J Rosenblat, PhD · Contact
    Recruiting
07

Registry details

Key details

Study ID
NCT05415878
Lead sponsor
Rosalind Franklin University of Medicine and Science
Collaborators
Manchester Metropolitan University
Responsible party
Noah Rosenblatt (Associate Professor, Rosalind Franklin University of Medicine and Science) — Principal investigator
First posted
Jun 13, 2022
Start date
Aug 2, 2023
Primary completion
Apr 30, 2027 (estimated)
Completion
May 30, 2027 (estimated)
Last update
Aug 19, 2026

Study contacts

Noah J Rosenblatt, PhD
Contact
noah.rosenblatt@rosalindfranklin.edu
8475788425
Ryan Crews, PhD
Contact
ryan.crews@rosalindfranklin.edu
Noah J Rosenblatt, PhD
principal investigator · Rosalind Franklin University of Medicine and Science

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion